Further to your conjecture on 1.5 v 2 mg studies. My understanding is effect size is close in aggregate BUT 2 mg is better for primary end points on pain and function. Read SW comments on confidence in achieving strong data set to allow PAR to monetise before read out. SW has chosen his words carefully and NOT given away too much here
- Forums
- ASX - By Stock
- PAR
- Where we at?
Where we at?, page-376
-
- There are more pages in this discussion • 331 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $76.95M |
Open | High | Low | Value | Volume |
22.5¢ | 23.5¢ | 22.0¢ | $65.40K | 290.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 96390 | 22.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
23.5¢ | 138166 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
12 | 91390 | 0.220 |
6 | 88958 | 0.215 |
5 | 131050 | 0.210 |
4 | 104982 | 0.205 |
6 | 184175 | 0.200 |
Price($) | Vol. | No. |
---|---|---|
0.235 | 138166 | 5 |
0.240 | 40833 | 1 |
0.250 | 15000 | 1 |
0.255 | 9785 | 1 |
0.260 | 26050 | 3 |
Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online